Long-Term Outcomes of Pegcetacoplan for GA Show Promise
Results of the 30-month data cut of the 3-year GALE open-label extension trial of pegcetacoplan for geographic atrophy showed that the drug produced clinically meaningful reductions in lesion growth.
United States Roger Goldberg American Society Of Retina Specialists Bay Area Retina Associates In Pleasanton Apellis Pharmaceuticals American Society
Source: medscape.com